Horizon Technology Finance Provides $15 Million Loan Facility to Bioness Medical

Horizon Technology Finance (HRZN) has provided a $15 million senior credit facility to Bioness Medical, with $10 million funded at closing and up to $5 million available to support future growth.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FARMINGTON, Conn.--(BUSINESS WIRE)-- Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $15 million senior credit facility to Bioness Medical, Inc. (“Bioness”), with an initial $10 million funded at closing, and up to $5 million available to support Bioness’s continued growth.

Bioness develops and commercializes FDA-approved neurorehabilitation technologies designed to improve mobility and function for individuals recovering from stroke, spinal cord injury, and other neurological conditions. Backed by Accelmed Partners, Bioness has established a leading position in the neurorehabilitation market through a portfolio of clinically validated products used across hospital, outpatient and home-based care settings.

“Providing flexible growth capital to innovative companies with proven business models and strong market positions is a core focus of Horizon’s venture lending platform,” said Paul Seitz, Chief Investment Officer of Horizon. “Our team has extensive experience partnering with healthcare and life sciences companies and delivering tailored financing solutions that help management teams execute on their growth objectives. Bioness is representative of the high-quality businesses we seek to support, and we are pleased to add another leading healthcare technology company to Horizon’s portfolio. We look forward to continuing to deploy capital in support of innovative companies across our target markets.”

“Horizon’s deep understanding of the life sciences sector and ability to structure a financing solution tailored to our needs made them an attractive partner,” said Todd Cushman, Co-Founder and Chief Executive Officer of Bioness. “This facility provides additional capital and flexibility as we continue investing in innovation, expanding our product portfolio and serving patients and healthcare providers around the world.”

About Horizon Technology Finance

Horizon Technology Finance Corporation (NASDAQ: HRZN), externally managed by Horizon Technology Finance Management LLC, an affiliate of Monroe Capital, is a leading specialty finance company that provides capital in the form of secured loans to venture capital and private equity-backed companies and publicly traded companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio’s return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional office in Pleasanton, California, and investment professionals located throughout the U.S. Monroe Capital is a premier asset management firm specializing in private credit markets across various strategies, including direct lending, technology finance, venture debt, opportunistic, structured credit, real estate and equity. To learn more, please visit horizontechfinance.com.

About Bioness Medical

Bioness Medical is a leading provider of advanced rehabilitation technologies designed to restore mobility, function, and independence. Its portfolio spans functional electrical stimulation, robotic gait training, and neuromodulation, supporting clinicians and healthcare systems worldwide with evidence-based solutions. Learn more at bionessmedical.com.

Forward-Looking Statements

Statements included herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Horizon’s filings with the Securities and Exchange Commission. Horizon undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260902236396/en/

Investor Relations:
ICR
Garrett Edson
ir@horizontechfinance.com
(860) 284-6450

Media Relations:
ICR
Chris Gillick
HorizonPR@icrinc.com
(646) 677-1819

Source: Horizon Technology Finance Corporation

Key Terms

senior credit facility financial

A senior credit facility is a large loan or revolving line of credit that a company borrows from banks or lenders and that has first claim on the company’s cash and assets if the business runs into financial trouble. Think of it as the “first in line” debt with stronger repayment priority and usually stricter rules, so investors watch it because its size, cost and covenants affect a company’s cash flow, risk profile and the value of equity and other creditors.

fda-approved regulatory

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

neurorehabilitation medical

Neurorehabilitation is the set of therapies and technologies used to help people regain or improve movement, thinking, speech, and daily function after injury or disease of the brain, spinal cord, or nerves — like retraining damaged wiring in a house so appliances work again. It matters to investors because demand, regulatory approvals, reimbursement rules, and technological advances can drive revenue and market growth for medical device makers, therapy providers, and drug developers in a growing, long‑term care market.